Khiron partners with specialized pain clinic,
Clínica del Dolor Lima ("CDL") to provide medical cannabis
treatment access to its over 10,000 chronic pain patient
population
TORONTO, Feb. 17, 2022 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a global
medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the opening of
another Zerenia™ location in Peru
in partnership with the renowned pain clinic, CDL.
Khiron in Peru
- This addition collectively brings the Company's total clinic
count to 16 globally, which includes presence in Colombia, Peru and the United
Kingdom
- Peru represented 5% of the
total Latin America unit sales in
2021
- In the second half of 2021, the Company opened its first
Zerenia™ clinic in Lima, in
partnership with Clínica Montesur. Since opening the clinic, over
80% of the consults resulted in cannabis prescriptions
- In August 2021, Khiron obtained
registration of its first two medical cannabis products in
Peru, available for sale
nationwide in late Q4 2021
The partnership with CDL
As a specialized pain clinic,
CDL already has pain management specialists and a patient base
exclusively related to chronic and acute pain. Starting
February 2022, Khiron will be
leveraging the CDL's existing infrastructure and reputation to
provide access to cannabinoid-based treatments to a growing group
of patients in Lima and
surrounding areas.
Alvaro Torres, Khiron CEO and
Director, commented, "In 2021, Peru represented around 5% of our total volume
sales in Latin America, and now
with our new partnership with CDL we believe we can increase our
sales cost-effectively by expanding Zerenia™ in Peru. In our first clinic in Peru, over 80% of total consultations resulted
in medical cannabis prescriptions, further validating our unique,
evidence and service-driven strategy. By establishing a new
pain-focused partnership with CDL in Lima, we plan to grow beyond our current
capacity and offer different treatment alternatives to more than
10,000 patients annually. Khiron recently began placing its
registered products in various drugstore channels across
Peru, improving the ease of access
to patients who are prescribed medical cannabis in the country, and
generating further growth. I am very excited about this partnership
as it also allows us to explore different business models for the
expansion of Zerenia™ across the region and we look forward to
generating higher growth in the Peruvian market with a population
of over 32 million people."
About Khiron Life Sciences Corp.
Khiron is a leading
global medical cannabis company with core operations in
Latin America and Europe. Leveraging wholly-owned medical health
clinics and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and focus on creating accessto drive
prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-adds-another-clinic-location-in-peru-301484780.html
SOURCE Khiron Life Sciences Corp.